These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22158653)

  • 1. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
    Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
    Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
    Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
    PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
    Ylitalo EB; Thysell E; Landfors M; Brattsand M; Jernberg E; Crnalic S; Widmark A; Hultdin M; Bergh A; Degerman S; Wikström P
    Clin Epigenetics; 2021 Jun; 13(1):133. PubMed ID: 34193246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.
    Nyquist MD; Dehm SM
    Horm Cancer; 2013 Apr; 4(2):61-9. PubMed ID: 23307762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
    Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
    PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.
    Magbanua MJ; Sosa EV; Scott JH; Simko J; Collins C; Pinkel D; Ryan CJ; Park JW
    BMC Cancer; 2012 Feb; 12():78. PubMed ID: 22373240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
    Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
    Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
    Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
    J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer.
    Zhang Y; Fan A; Li Y; Liu Z; Yu L; Guo J; Hou J; Li X; Chen W
    Cancer Lett; 2023 Jul; 566():216244. PubMed ID: 37244445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
    Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
    Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
    Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
    J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
    Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
    Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
    Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
    Choucair K; Ejdelman J; Brimo F; Aprikian A; Chevalier S; Lapointe J
    BMC Cancer; 2012 Nov; 12():543. PubMed ID: 23171135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.